|1.||Wald, Anna: 11 articles (01/2013 - 10/2003)|
|2.||Tyring, Stephen: 9 articles (04/2012 - 09/2006)|
|3.||Tyring, Stephen K: 8 articles (08/2012 - 10/2002)|
|4.||Warren, Terri: 7 articles (04/2008 - 10/2003)|
|5.||Corey, Lawrence: 5 articles (02/2012 - 01/2004)|
|6.||Fife, Kenneth H: 5 articles (01/2009 - 10/2006)|
|7.||Suzuki, Hiroshi: 4 articles (04/2013 - 08/2010)|
|8.||Mendoza, Natalia: 4 articles (08/2011 - 05/2008)|
|9.||Brennan, Clare A: 4 articles (01/2009 - 10/2003)|
|10.||Legendre, Christophe: 4 articles (05/2006 - 10/2002)|
04/01/1997 - "This study has demonstrated that once daily valaciclovir (500 mg), is highly effective and well tolerated for the suppression of recurrent genital HSV infection. "
01/01/2009 - "Our study is the first to demonstrate a significant reduction in viral shedding with valacyclovir 1 g daily compared to placebo in a population of subjects newly diagnosed with HSV-2 infection."
07/01/2009 - "It is concluded, that continuous suppressive therapy of HSV infections with valacyclovir is safe and effective treatment, which strongly prevents reoccurrence or transmissions of HSV infections to sexual partners. "
08/01/2002 - "We concluded that the 16 CFS patients (included in both phases of this study) with EBV-persistent infection (EBV single-virus subset) are improved after 6 months of continuous pharmacokinetic dosing with valacyclovir. "
08/01/2002 - "This study was designed to determine safety and efficacy of a 6-month trial of valacyclovir in single-virus Epstein-Barr virus (EBV) persistent infection. "
|2.||Herpes Genitalis (Genital Herpes)
07/01/1999 - "Valacyclovir HCl was highly effective and well tolerated as continuous suppressive therapy in men and women with recurrent genital herpes. "
09/01/1998 - "Thus, valaciclovir is highly effective and well tolerated for suppression of recurrent genital herpes. "
11/01/2004 - "Valacyclovir at 500 mg twice daily was effective in preventing or delaying recurrences of genital herpes compared with placebo (hazard ratio, 0.20; 95% CI, 0.13-0.30; P<.001) and with valacyclovir at 1000 mg once daily (hazard ratio, 0.56; 95% CI, 0.40-0.80; P=.001), in 6-month and 48-week studies, respectively. "
10/01/1999 - "A double-blind, randomized, controlled, multicriteria equivalence trial was conducted to determine whether od treatment with valacyclovir 1000 mg is as effective as bd treatment with 500 mg in patients with recurrent genital herpes. "
07/01/2008 - "Valacyclovir 1 g once daily administered for 24 weeks was well-tolerated and effective in suppressing genital herpes recurrences in immunocompetent newly diagnosed persons without an established recurrence pattern."
01/01/2014 - "[Ophthalmic zoster of th eyelid: good outcome with valaciclovir]."
09/01/2000 - "Current wholesale prices indicate that valacyclovir is the more cost-effective treatment for herpes zoster ($83.90 vs $140.70 per course)."
05/01/2007 - "Oral valacyclovir 1.5 g bid is safe and effective for the treatment of uncomplicated herpes zoster in immunocompetent patients over 18 years of age. "
05/01/2008 - "The objective of this study was to assess the safety and efficacy of an oral dosage of valacyclovir, 1 g TID versus 2 g TID, for the treatment of herpes zoster in immunocompromised patients > or =18 years of age. "
05/01/2007 - "To demonstrate the safety and efficacy of oral valacyclovir 1.5 g twice daily (bid) for the treatment of uncomplicated herpes zoster in immunocompetent patients over 18 years of age. "
08/01/2012 - "No EPB-348 group was non-inferior to valacyclovir for time to cessation of new lesion formation or time to cessation of pain by Day 120, though no significant differences occurred between treatment groups. "
09/01/2004 - "The mean time to pain cessation was significantly less in the valacyclovir group (3.2 days) than in the placebo group (6.2 days) (P = .006). "
04/01/2004 - "The effect of valacyclovir on pain and tenderness and FIQ did not differ from placebo. "
03/01/2003 - "The time to lesion healing and time to cessation of pain and/or discomfort were statistically significantly reduced with valacyclovir compared to placebo. "
08/12/1996 - "Valaciclovir therapy provided a clinically significant benefit to patients that included shortening of the duration of lesions, the duration of pain or discomfort, and the duration of virus shedding. "
07/01/1995 - "Treatment with valaciclovir also significantly reduced the duration of postherpetic neuralgia and decreased the proportion of patients with pain persisting for 6 months (19.3 versus 25.7%). "
07/01/2006 - "Improvement of postherpetic neuralgia after treatment with intravenous acyclovir followed by oral valacyclovir."
08/01/2011 - "To evaluate the efficacy of treatment with gabapentin plus valacyclovir hydrochloride for the prevention of postherpetic neuralgia in patients with acute herpes zoster. "
08/01/2011 - "Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study."
08/01/2011 - "Prevent rather than treat postherpetic neuralgia by prescribing gabapentin earlier in patients with herpes zoster: comment on "incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster"."
|4.||Antiviral Agents (Antivirals)
|1.||Transplantation (Transplant Recipients)
|3.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
|4.||Stem Cell Transplantation